Brief Summary

This trial is designed to evaluate the efficacy and safety of UGN-101 administered to the upper urinary tract (UUT) in patients who were treated in Trial TC-UT-03, found to be a complete response (CR) at the Primary Disease Evaluation (PDE) 1 Visit and are subsequently found to have a documented recurrence of low grade (LG) upper tract urothelial carcinoma (UTUC) at follow up (FU).

Detailed Description

This is an open-label, single-arm, Phase 3b multicenter extension trial, designed to evaluate
the efficacy and safety of UGN-101 administered to the UUT in patients who were treated in
Trial TC-UT-03, found to be a CR at the PDE 1 Visit, and are subsequently found to have a
documented recurrence of LG UTUC at FU.

Upon signing of informed consent, the patients will undergo their routine ureteroscopy to
assess durability. A biopsy will be performed at Visit 0, if appropriate, to confirm evidence
of tumor. If a high grade (HG) UTUC is confirmed by biopsy and/or cytology, the patient will
be excluded from the retreatment trial. Eligible patients with confirmed LG non-invasive UTUC
will be treated with 3 to 6 once-weekly instillations of UGN-101 in a retrograde fashion, per
investigator's discretion.

Five weeks (± 1 week) following the last Investigational product (IP) treatment, the patient
will be assessed for efficacy and safety at the PDE 2 Visit. At this visit, the patient will
undergo ureteroscopy and any remaining lesions will be biopsied, and UUT urine wash will be
collected for cytology.

Patients demonstrating CR at the PDE 2 Visit will undergo FU visits at 3, 6, 9, and 12 months
(± 2 weeks) following the PDE 2 Visit.

The trial will be approximately 15 months, per patient: a 3- to 6-week treatment period,
followed by 4 to 6 weeks post-treatment leading up to the PDE 2 Visit, and a 12-month FU post
PDE 2 Visit. This trial will follow the Steering Committee, and a Data Monitoring Committee
(DMC) has been assigned as established for the primary trial TC-UT-03.